Private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials. This capital deployment represents more than opportunistic investment—it reflects recognition that established clinical trial software companies require growth equity rather than venture capital to reach their full potential. While early-stage investors focus on product development and market validation, growth-oriented firms like Waud Capital Partners provide the operational expertise and scaling capital that mature clinical trial technology platforms need to capture market leadership positions.
Reeve Waud’s Chicago-based firm has refined this growth equity approach across 30 years of healthcare technology investment, generating a track record that demonstrates why clinical trial software companies benefit more from experienced operators than from traditional venture capital. The firm’s systematic approach to building market-leading healthcare platforms provides a template for understanding optimal capital strategies in clinical research technology.
Growth vs. Early-Stage Capital
Established clinical trial software companies face scaling challenges that venture capital typically cannot address effectively. These platforms have proven product-market fit and established customer bases but require significant operational improvements, market expansion, and often consolidation of competitive solutions to achieve market leadership.
Waud Capital’s investment criteria include “an equity investment between $75 and $200 million” targeting companies with “strong growth potential,” which aligns precisely with the capital needs of mature clinical trial software platforms. These companies need substantial capital for sales team expansion, technology integration, and strategic acquisitions rather than product development funding that characterizes venture investment.
The firm seeks to “partner with strong management teams to build market-leading companies,” addressing the leadership development needs that distinguish growth equity from venture capital. Clinical trial software companies require executives who understand both healthcare technology and pharmaceutical industry requirements—expertise that Reeve Waud’s team helps identify and recruit.
Operational Expertise Matters
According to Waud Capital’s approach, the firm’s Portfolio Operations team “actively works alongside the company and its new leadership, optimizing operations and building the foundations for higher profitability.” This hands-on operational support becomes particularly valuable for clinical trial software companies that must integrate complex healthcare data workflows while maintaining regulatory compliance.
Reeve Waud has experience scaling healthcare technology platforms like Integrated Practice Solutions, described as “a market leading provider of practice management and EHR software to healthcare practices in chiropractic, optometry, speech and other therapy markets.” The operational challenges of serving fragmented healthcare markets with compliance-intensive software requirements directly parallel the challenges facing clinical trial management system providers.
The firm’s healthcare portfolio includes technology-enabled services platforms and healthcare IT solutions that require similar operational excellence, providing Reeve Waud’s team with relevant experience for supporting clinical trial software scaling initiatives.
The Exit Strategy Advantage
Waud Capital’s track record includes successful healthcare IT exits that demonstrate the firm’s ability to position companies for strategic acquisitions. The firm’s approach to building and scaling healthcare technology platforms creates the strategic premium that specialized healthcare technology platforms can command when properly positioned.
Reeve Waud has led or overseen “more than 500 company acquisitions” throughout his career, providing understanding of exit strategies that maximize returns for management teams and investors. The firm’s healthcare platform investments achieve “an average revenue growth of 400%+” for realized investments, demonstrating value creation that positions companies for premium exits.
Clinical trial software companies benefit from growth equity providers who understand both the operational requirements of scaling healthcare technology platforms and the exit strategies that maximize returns for management teams and investors. Reeve Waud’s three-decade track record demonstrates why growth-oriented private equity represents optimal capital for mature clinical trial technology companies seeking market leadership positions.
